Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1311024 | 0.99 | TLR9 (0.32) | TLR9TLR8TLR7RIPK1TACR1 | |
| SCHEMBL1311333 | 0.79 | ALDH1A1 (0.38) | LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1311047 | 0.78 | ALDH1A1 (0.37) | LMNASMN1; SMN2 | |
| SCHEMBL1578305 | 0.72 | AAK1 (0.36) | LMNASMN1; SMN2 | |
| SCHEMBL1336968 | 0.68 | LMNA (0.43) | RIPK1TACR1LMNASMN1; SMN2 | |
| SCHEMBL1310507 | 0.68 | ERCC1 (0.36) | LMNASMN1; SMN2 | |
| SCHEMBL1310401 | 0.68 | KMT2A (0.38) | SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1311860 | 0.67 | ERCC1 (0.35) | LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1334739 | 0.67 | LMNA (0.42) | RIPK1TACR1LMNASMN1; SMN2 | |
| SCHEMBL1310852 | 0.67 | SMN1; SMN2 (0.41) | LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275638-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | claimed |
| US-20110275638-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275638-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ADIPOR2, GPR119, ADIPOR1 | TLR9 1501/4885TLR8 864/4885TLR7 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.